Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study

Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study

IntroductionCheckpoint inhibitors, such as PD1 inhibitors, represent an important pillar in the therapy of advanced malignancies of the head and neck region. The most relevant complications are immune-related adverse effects (irAEs), which represent an immense burden for patients. Currently, no suff...

Full description

Bibliographic Details
Main Authors:	Frederic Jungbauer, Annette Affolter, Christoph Brochhausen, Anne Lammert, Sonja Ludwig, Kirsten Merx, Nicole Rotter, Lena Huber
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Oncology
Subjects:	HNSCC (head and neck squamous cell carcinoma) HNC (head and neck cancer) checkpoint inhibition irAE irAE diagnostic approach PD-L1
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1287178/full

Similar Items

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature
by: Jaime Rubio-Perez, et al.
Published: (2022-10-01)

Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
by: Almog Shalit, et al.
Published: (2023-01-01)

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
by: Yutaka Takahara, et al.
Published: (2023-09-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024-02-01)

HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment
by: Sophia Gandarillas, et al.
Published: (2024-01-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023-12-01)

Fever of unknown origin associated with immune checkpoint inhibitors
by: Xu Tong, et al.
Published: (2024-03-01)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
by: Vasiliki Nikolaou, et al.
Published: (2023-03-01)

Successful management of severe bronchial asthma exacerbated by anti‐PD‐L1 treatment: A report of two cases
by: Toshiyuki Sumi, et al.
Published: (2021-11-01)

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
by: Biagio Ricciuti, MD, et al.
Published: (2020-11-01)

Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series
by: Sarah Picard, et al.
Published: (2021-07-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
by: Alicia Quilez, MD, et al.
Published: (2020-03-01)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
by: Ji Li, et al.
Published: (2022-05-01)

Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis
by: Naoki Hamada, et al.
Published: (2021-12-01)

Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
by: Alice Indini, et al.
Published: (2021-03-01)

Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody
by: Shin Urai, et al.
Published: (2023-11-01)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
by: Panpan Chen, et al.
Published: (2022-10-01)

Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab
by: Yuka Maya, MD, et al.
Published: (2020-12-01)

Immune Checkpoint Inhibitor-Associated Myocarditis
by: Grigorios Chatzantonis, MD, et al.
Published: (2020-04-01)

The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?
by: Robin Reschke, et al.
Published: (2024-03-01)

Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
by: Elisa Longhitano, et al.
Published: (2023-03-01)

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
by: Yuki Haruta, et al.
Published: (2024-02-01)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
by: Cinzia Vetrei, et al.
Published: (2021-06-01)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
by: Deborah L. Burnett, et al.
Published: (2022-07-01)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
by: Chiao-En Wu, et al.
Published: (2020-10-01)

Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
by: David Dora, et al.
Published: (2023-02-01)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
by: Lorena Arribas, et al.
Published: (2021-06-01)

Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis
by: Kazuhiro Nishiyama, et al.
Published: (2023-02-01)

A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
by: Philip Friedlander, et al.
Published: (2018-09-01)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
by: Guili Huang, et al.
Published: (2022-11-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Nail toxicity with nail bed ulceration associated with pembrolizumab
by: Shintaro Maeda, et al.
Published: (2023-12-01)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
by: Gunther Glehr, et al.
Published: (2022-09-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
by: T. Anders Olsen, et al.
Published: (2022-03-01)

Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
by: Lærke K. Tolstrup, et al.
Published: (2022-01-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors
by: Eva Baier, et al.
Published: (2023-04-01)

Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
by: Rosa Jiménez-Alejandre, et al.
Published: (2022-09-01)